Πέμπτη 31 Αυγούστου 2017

Savolitinib Heads for Phase III Trial in PRCC [News in Brief]

A phase II trial of savolitinib, a MET inhibitor, found that the drug induced partial responses in some patients with papillary renal cell carcinoma and was well tolerated, prompting drug makers Chi-Med and AstraZeneca to launch a phase III study.



http://ift.tt/2eJMTBo

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου